Scholarlink

Background <p>Mesenchymal stem cells (MSCs)-based and MSCs-derived extracellular vesicle (EV) therapies, have garnered significant attention as potential treatments for severe Coronavirus disease 19 (Covid-19), leading to evaluation in numerous clinical trials. This interest stems from the observed ability of MSCs, and their EVs, to mitigate the hyper-inflammatory state that characterizes severe cases of the disease. However, despite the promising preclinical and early clinical results, the precise mechanisms of action remain unclear, hindering therapy optimization.</p> Methods <p>This study investigated the response of Wharton’s jelly-derived mesenchymal stem cells (WJ-MSCs) to a diverse panel of sera collected from multiple hospitalized Covid-19 patients, aiming to recapitulate in vitro the spectrum of inflammatory conditions MSCs encounter in vivo.</p> Results <p>Exposure to Covid-19 serum activated WJ-MSCs, increasing proliferation and RNA/protein synthesis. Transcriptomic analysis revealed an early and significant downregulation of the inflammation-related long non-coding RNAs (lncRNAs) <i>NEAT1</i> and <i>MALAT1</i>. This downregulation of <i>NEAT1</i> and <i>MALAT1</i>, triggered by Covid-19 serum, suggests a potential mechanism by which WJ-MSCs may limit excessive inflammation. Importantly, reducing <i>MALAT1</i> (and to a lesser extent <i>NEAT1</i>) expression in WJ-MSCs enhanced the therapeutic potential of MSC-derived EVs. This suggests that targeting pro-inflammatory lncRNAs in parental cells could be a promising therapeutic strategy for managing Covid-19 and other inflammatory lung diseases.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Modulation of NEAT1 and MALAT1 expression in WJ-MSCs by Covid-19 serum: a foundation for EVs-mediated therapy

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年11月10日

查看全文
  • Arantza Infante,
  • Leire Cabodevilla,
  • Blanca Gener,
  • Daniela Gerovska,
  • Marcos J. Araúzo Bravo,
  • Victoria Boado,
  • Tomas Muñoz,
  • Milagros Iriberri,
  • Claudio Catalli,
  • Esperanza González,
  • Juan M. Falcón-Pérez,
  • Clara I. Rodríguez

摘要

Background

Mesenchymal stem cells (MSCs)-based and MSCs-derived extracellular vesicle (EV) therapies, have garnered significant attention as potential treatments for severe Coronavirus disease 19 (Covid-19), leading to evaluation in numerous clinical trials. This interest stems from the observed ability of MSCs, and their EVs, to mitigate the hyper-inflammatory state that characterizes severe cases of the disease. However, despite the promising preclinical and early clinical results, the precise mechanisms of action remain unclear, hindering therapy optimization.

Methods

This study investigated the response of Wharton’s jelly-derived mesenchymal stem cells (WJ-MSCs) to a diverse panel of sera collected from multiple hospitalized Covid-19 patients, aiming to recapitulate in vitro the spectrum of inflammatory conditions MSCs encounter in vivo.

Results

Exposure to Covid-19 serum activated WJ-MSCs, increasing proliferation and RNA/protein synthesis. Transcriptomic analysis revealed an early and significant downregulation of the inflammation-related long non-coding RNAs (lncRNAs) NEAT1 and MALAT1. This downregulation of NEAT1 and MALAT1, triggered by Covid-19 serum, suggests a potential mechanism by which WJ-MSCs may limit excessive inflammation. Importantly, reducing MALAT1 (and to a lesser extent NEAT1) expression in WJ-MSCs enhanced the therapeutic potential of MSC-derived EVs. This suggests that targeting pro-inflammatory lncRNAs in parental cells could be a promising therapeutic strategy for managing Covid-19 and other inflammatory lung diseases.